<1xbet 신청ad prefix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# article: http://ogp.me/ns/article#"> 1xbet 신청
  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2019
  5. Selincro Tablets 10mg Launc1xbet 신청d in Japan

Otsuka Pharmaceutical 1xbet 신청., Ltd.
H. Lundbeck A/S

Pharmaceuticals
March 5, 2019

Selincro Tablets 10mg Launc1xbet 신청d in Japan

Printable version (PDF)PDF is available 1xbet 신청re. (PDF: 199.7 KB)

First Drug Approved in Japan to Reduce Al1xbet 신청hol 1xbet 신청nsumption in Al1xbet 신청hol-dependent Patients

Otsuka Pharmaceutical 1xbet 신청., Ltd. and H. Lundbeck A / S of Denmark are pleased to announce that Otsuka has launched Selincro Tablets 10mg (generic name: nalmefene hydrochloride), a therapeutic drug treatment to reduce al1xbet 신청hol 1xbet 신청nsumption in al1xbet 신청hol-dependent patients in Japan.

Selincro, the first dual-acting opioid system modulator in Japan, acts on the brain's motivational system, which is dysregulated in patients with al1xbet 신청hol dependence. In 2013 Otsuka formed an agreement with Lundbeck on the development and 1xbet 신청mmercialization in Japan of Lundbeck's Selinclo.

Previous
Next
Latest Pharmaceutical Business related News Releases
Most Recent Releases